APM
CAPR icon

Avidity Partners Management’s Capricor Therapeutics CAPR Stock Holding History

Avidity Partners Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-239,000
Closed -$2.27M – 64
2025
Q1 		$2.27M Buy
+239,000
New +$3.32M 0.43% 54

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Avidity Partners Management's CAPR Position: Q2 2025 in Review

Avidity Partners Management sold out of Capricor Therapeutics (CAPR) in Q2 2025, closing a stake of 239,000 shares — an estimated $2.27M sold.

Avidity Partners Management first reported a position in CAPR in Q1 2025 and held it in 1 quarter. The position peaked at $2.27M in Q1 2025. 107 funds tracked by Wall St. Rank hold CAPR as of Q2 2025.

  • Avidity Partners Management reported no remaining Capricor Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Avidity Partners Management sold 239,000 Capricor Therapeutics shares in Q2 2025, an estimated $2.27M.
  • Avidity Partners Management first reported a position in Capricor Therapeutics in Q1 2025 and held it in 1 quarter.
  • Avidity Partners Management's Capricor Therapeutics position peaked at $2.27M in Q1 2025.
  • 107 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.